CLOV · Clover Health Investments, Corp. /De
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $81.2M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Net income non-GAAP | $80.1M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted SG&A non-GAAP | $231.4M | Six Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted SG&A as a % of Total revenues non-GAAP | 15.5% | Six Months Ended June 30, 2026 | — |
| Average Medicare Advantage membership | 155,723 | Six Months Ended June 30, 2026 | — |
|
|
|||
| Consolidated Gross profit non-GAAP | $312.5M | Six Months Ended June 30, 2026 | — |
| Insurance BER non-GAAP | 87.1% | Six Months Ended June 30, 2026 | — |
| Insurance members | 157,309 | June 30, 2026 | — |
| Normalized Insurance BER non-GAAP | 91.5% | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLOV
this stock
Clover Health Investments, Corp. /De
|
$2.44B | +95.7% | +40.3% | — | 5.3% |
|
UNH
Unitedhealth Group Inc
|
$360.59B | +21.7% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$124.26B | +22.4% | +7.8% | 25.6 | 1.5% |
|
ELV
Elevance Health, Inc.
|
$86.82B | +14.2% | +12.5% | 17.7 | 2.6% |
|
CI
Cigna Group
|
$74.66B | +2.7% | +11.2% | 11.7 | 1.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLOV | -3.4% | -0.4% | +133.5% | +10.3% | +95.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -3.8% | -4.9% | +119.7% | +6.4% | +81.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.